tarafenacin

Tarafenacin is a small molecule antimuscarinic agent under development for the treatment of overactive bladder (OAB) and urinary incontinence. It acts as an antagonist of the muscarinic acetylcholine receptor M3, which mediates contraction of bladder smooth muscle. By blocking this receptor, tarafenacin reduces involuntary bladder contractions and helps decrease symptoms such as frequent urination and urgency. Clinical studies have shown that tarafenacin at 0.4 mg daily significantly decreases the number of micturitions per day compared to placebo after 12 weeks of treatment in patients with OAB[7][10]. The most common adverse event reported is dry mouth; other side effects are similar to those seen with other antimuscarinics.

Brand names

tarafenacin

Other names

SVT-40776SVT40776SVT 40776tarafenacinSVT-40776 D-tartrateSVT40776 D-tartrateSVT 40776 D-tartrate